Biofrontera Inc. (BFRI)
(Delayed Data from NSDQ)
$1.03 USD
+0.02 (1.98%)
Updated May 31, 2024 03:56 PM ET
After-Market: $1.05 +0.02 (1.94%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Brokerage Reports
0 items in cart
Biofrontera Inc. [BFRI]
Reports for Purchase
Showing records 1 - 20 ( 59 total )
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
1Q24: Sales Headwind From Change Healthcare Cybersecurity Breach Now Over
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
4Q23: Renegotiates Better Ameluz Terms, Ameluz sNDA PDUFA Set For 4Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Renegotiates Better Ameluz Terms, Adds $15.5M Cash, Ameluz sNDA PDUFA Set
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology and Medical Device Conference Note
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
3Q23: 25% Y/Y Revenue Growth For 2023, Cash Flow Positivity In Mid-2025
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Preannounced 3Q23 Revenue, Kept 2023 Guidance, New Ameluz Formulation
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: HC Opportunities Conference in NYC on October 12th
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: HC Opportunities Conference in NYC on October 12th
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Safety Trial With 3 Ameluz Tubes Succeeds, Expecting 2024 Label Expansion
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
2Q23: 25% YoY Revenue Growth For ''23, To Be Cash Flow Positive Around 1Q25
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Pre-Releases 2Q23 Revenue Range, Developing a Low-Cost, Portable PDT Lamp
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
USPTO Issues Patent for PDT Protocol Resulting In Reduced Discomfort
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J